COPENHAGEN, July 29 (Reuters) - Novo Nordisk named
Maziar Mike Doustdar as CEO on Tuesday as the Wegovy maker seeks
to revive sales and its share price, hit by worries it is losing
the obesity drug race it started to U.S. rival Eli Lilly ( LLY ).
The appointment comes after the abrupt removal in May of CEO
Lars Fruergaard Jorgensen by Novo and the Novo
Nordisk Foundation - the Danish company's controlling
shareholder.